[go: up one dir, main page]

Kagan et al., 2015 - Google Patents

First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testing

Kagan et al., 2015

View PDF @Full View
Document ID
8399860747943860826
Author
Kagan K
Wright D
Nicolaides K
Publication year
Publication venue
Ultrasound in Obstetrics & Gynecology

External Links

Snippet

Objective To examine performance of screening for major trisomies by a policy of first‐line assessment of risk according to maternal age, fetal nuchal translucency thickness (NT) and ductus venosus pulsatility index for veins (DV‐PIV) followed by cell‐free DNA (cfDNA) …
Continue reading at obgyn.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions

Similar Documents

Publication Publication Date Title
Kagan et al. First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testing
Gil et al. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell‐free DNA test contingent on results from first‐trimester combined test
Santorum et al. Accuracy of first‐trimester combined test in screening for trisomies 21, 18 and 13
Nicolaides et al. First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testing
Wright et al. A unified approach to risk assessment for fetal aneuploidies
Canick et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies
Sarno et al. Prospective first‐trimester screening for trisomies by cell‐free DNA testing of maternal blood in twin pregnancy
McKanna et al. Fetal fraction‐based risk algorithm for non‐invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell‐free fetal DNA
Gil et al. Implementation of maternal blood cell‐free DNA testing in early screening for aneuploidies
Prats et al. Systematic review of screening for trisomy 21 in twin pregnancies in first trimester combining nuchal translucency and biochemical markers: a meta‐analysis
Syngelaki et al. Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on first‐trimester screening for chromosomal abnormalities
Robson et al. National decline in invasive prenatal diagnostic procedures in association with uptake of combined first trimester and cell‐free DNA aneuploidy screening
Abele et al. First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow
Kagan et al. First‐trimester risk assessment based on ultrasound and cell‐free DNA vs combined screening: a randomized controlled trial
Wax et al. Noninvasive prenatal testing: impact on genetic counseling, invasive prenatal diagnosis, and trisomy 21 detection
Karadzov‐Orlic et al. Improved diagnostic accuracy by using secondary ultrasound markers in the first‐trimester screening for trisomies 21, 18 and 13 and Turner syndrome
Persico et al. Cell‐free DNA testing in the maternal blood in high‐risk pregnancies after first‐trimester combined screening
Wiechec et al. First trimester tricuspid regurgitation and fetal abnormalities
Rosner et al. Detection of genetic abnormalities by using CVS and FISH prior to fetal reduction in sonographically normal appearing fetuses
Veduta et al. The first trimester combined test for aneuploidies–a single center experience
Pettit et al. The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience
Lichtenbelt et al. Factors determining uptake of invasive testing following first‐trimester combined testing
Colosi et al. First trimester contingent screening for trisomies 21, 18, 13: is this model cost efficient and feasible in public health system?
Wagner et al. First‐trimester ultrasound screening for trisomy 21 based on maternal age, fetal nuchal translucency, and different methods of ductus venosus assessment
Ashoor Al Mahri et al. Evolution in screening for Down syndrome